KYTX

Kyverna Therapeuticsdistress 5/10 · elevated risk

$7.22-2%today-36% from 52w high

kyvernatx.com129 employeesFounded 2018EmeryVille, CABiotechnology

Immunology / Inflammation 1

Lead: stiff person syndrome · target CD19

Revenue

pre-revenue

Liquidity

$236M

Runway

1.6 yrs

Shares 1y

+41%

Price & events

-31.3% over 6M

CatalystRating changeDilutionFinancingdashed = today

-2.4%

-3.0%

-14.4%

-19.3%

-26.0%

+66.7%

-23.3%

—

-76.0%

All

Overview

Market Cap: $438.88M
Volume: 139.93K
52 Week Range: $3.02 – $11.25
Total Shares: 60.80M
Float Shares: 35.55M
Short %: 13.99%
% Held by Insiders: 7.10%
% Held by Institutions: 74.72%
RVOL: 0.11x
Beta: 1.88

Pipeline stages · 2 programs

KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimen

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2026-08

Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-09

Pipeline · 6 trials · 4 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-08 Estimated 50% readout ~2026-09-15 final ~2027-08-31	Phase 1/2	KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimenrmatorphan	Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV	6	active not recruiting
2027-04 Estimated 50% readout ~2027-05-16	Phase 2	KYV-101, Standard lymphodepletion regimen, Anti-CD20 mABrmatorphan	Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, MS	—	active not recruiting
2027-09 Estimated 50% readout ~2027-11-15	Phase 2/3	Standard of Care Treatment, Standard lymphodepletion regimen, KYV-101	Myasthenia Gravis, Generalized Myasthenia Gravis	—	recruiting
2028-10 Estimated 50% readout ~2028-11-15	Phase 1/2	KYV-101 anti-CD19 CAR-T cell therapy, Standard lymphodepletion regimenrmatorphan	Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV	—	active not recruiting
2026-04	Phase 2	Standard lymphodepletion regimen	Stiff-Person Syndrome, SPS	25	active not recruiting

Show all 6 trials · 1 more ▾

Readout	Phase	Drug	Indication	Enroll	Status
2026-03	Phase 1/2	KYV-101, Standard lymphodepletion regimenrmatorphan	Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria	3	active not recruiting

Catalyst news & presentations · 13

2026Guided 40%conferencedata presentationsecondaryPhase 2mivocabtagene autoleucel · Present full SPS data at medical conferenceSEC 8-K
2026Guided 40%conferencedata presentationsecondaryPhase 2KYV-101 · Report updated data for Phase 2 portion of KYSA-6 Phase 2/3 trialSEC 8-K
2026regulatory submissionFiled (NDA/BLA)KYV-101 · BLA filingSEC 8-K
2026-08-12Estimated 45%earningsEarningsEarnings releaseyahoo
first half of 2026regulatory submissionFiled (NDA/BLA)mivocabtagene autoleucel · Submit BLA to FDA for SPSSEC 8-K
1H 2026regulatory submissionFiled (NDA/BLA)KYV-101 · BLA filingSEC 8-K
1H 2026readoutPhase 2KYV-101 · Report topline pivotal Phase 2 dataSEC 8-K
April 22, 2026conferencedata presentationsecondarymiv-cel · Conference call to review Phase 2 dataSEC 8-K
early 2026readoutPhase 2KYV-101 · Topline registrational dataSEC 8-K
2H 2025regulatory submissionFiled (NDA/BLA)KYV-102 · File KYV-102 investigational new drug applicationSEC 8-K
2H 2025readoutPhase 2KYV-101 · Report interim Phase 2 dataSEC 8-K
by year-end 2025trial initiationsecondaryPhase 3KYV-101 · Initiate enrollment for registrational Phase 3 trialSEC 8-K
mid-2025enrollment completesecondaryPhase 2KYV-101 · Complete pivotal Phase 2 enrollmentSEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 60,795,212 · 4 offerings/1y · 0 PIPEs

2026-07-098-Kmaterial_agreement
2026-04-02424B5offering
2026-04-02EFFECTshelf_effective
2026-03-26S-3shelf_registration
2025-12-188-Kmaterial_agreement
2025-12-18424B5offering
2025-12-17FWPoffering

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

no consensus

2026-06-03HC Wainwright & Co.Buy
2026-05-15HC Wainwright & Co.Buy
2026-05-13JP MorganOverweight
2026-04-23HC Wainwright & Co.Buy
2025-12-16Wells FargoOverweight
2025-12-04Morgan StanleyOverweight

Competitors — CD19

ZBIOZenas BioPharma, Inc.$2.0B · D3
IPSCCentury Therapeutics, Inc.$381M · D6
FATEFATE THERAPEUTICS INC$294M · D3
NKTXNkarta, Inc.$166M · D3
CRBUCaribou Biosciences, Inc.$160M · D0
ATRAAtara Biotherapeutics, Inc.$71M · D7

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.